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ABSTRACT
Background. Gitelman syndrome (GS) is a rare recessively in-
herited renal tubulopathy associated with renal potassium (K)
and magnesium (Mg) loss. It requires lifelong K and Mg sup-
plementation at high doses that are at best unpalatable and at
worst, intolerable. In particular, gastrointestinal side effects
often limit full therapeutic usage.
Methods. We report here the analysis of a cohort of 28 adult
patients with genetically proven GS who attend our specialist
tubular disorders clinic, in whomwe initiated the use of amodi-
ﬁed-release Mg preparation (slow-release Mg lactate) and who
were surveyed by questionnaire.
Results. Twenty-ﬁve patients (89%) preferred the new treatment
regimen. Of these 25, 17 (68%) regarded their symptom burden as
improved and seven reported no worsening. Of the 25 who were
not Mg-treatment naïve, 13 (59%) patients reported fewer side ef-
fects, 7 (32%) described them as the same and only 2 (9%) consid-
ered side effects to be worse. Five were able to increase their dose
without ill-effect. Overall, biochemistry improved in 91% of the 23
patients switched from therapywith other preparationswho chose
to continue the modiﬁed-release Mg preparation. Eleven (48%)
improved both their Mg and K mean levels, 3 (13%) improved
Mg levels only and in 7 cases (30%), K levels alone rose.
Conclusions. Patient-reported and biochemical outcomes
using modiﬁed-release Mg supplements were very favourable,
and patient choice should play a large part in choosingMg sup-
plements with GS patients.
Keywords: Gitelman syndrome, hypomagnesaemia, patient-
reported outcomes, tubulopathy
INTRODUCTION
Gitelman syndrome (GS) is a rare inherited renal electrolytewasting
disorder primarily characterized by hypokalaemia, hypochloraemic
metabolic alkalosis, hypomagnesaemia and hypocalciuria. The
condition was ﬁrst described in 1966 [1]. It was originally thought
to be a variant of Bartter syndrome until 1996when Simon et al. [2]
identiﬁed the underlying causative mechanism as loss-of-function
mutations in SLC12A3, which encodes the sodium chloride co-
transporter in the distal convoluted tubule. Inheritance is autosomal
recessive and prevalence is estimated at 1:40 000 (http://ghr.nlm.nih.
gov/condition/gitelman-syndrome).
GS symptoms are predominantly related to chronic
hypokalaemia and hypomagnesaemia and commonly include
generalized fatigue, muscle weakness, muscle cramps, thirst,
polyuria, carpopedal spasm, paraesthesiae, palpitations and
joint pain. More severe manifestations such as chondrocalcino-
sis requiring joint replacement [3], seizures, rhabdomyolysis,
cardiac arrhythmias and sudden cardiac arrest have also been
reported [4]. The frequency and severity of symptoms and
signs are variable, but contrary to earlier descriptions of GS,
and as reported by Cruz et al. in 2001 [5], few patients are
truly asymptomatic.
The aims of treatment are to improve patient symptoms,
quality of life and serum electrolyte levels, and to ensure cardiac
rhythm stability. However, it is often not possible to achieve
electrolyte levels within the normal range because of poor tol-
erability of available medications. Standard treatment includes
the use of a high-salt/potassium/magnesium diet and oral mag-
nesium (Mg) and potassium (K) supplements, sometimes to-
gether with K-sparing diuretics (concomitant hypotension
permitting). The need for Mg and K replacement is lifelong© The Author 2016. Published by Oxford University Press on behalf of
ERA-EDTA. This is an Open Access article distributed under the terms of the
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and oral dose requirements may be very high. Intravenous
electrolyte replacement is best reserved for critically low
serum Mg/K, emergency situations or elective surgery in GS
patients.
While hypomagnesaemia is a common ﬁnding in the chron-
ically sick, the elderly, in malabsorbtive syndromes and in diet-
ary deﬁciency, very little information exists concerning the
bioavailability, efﬁcacy and tolerability of Mg compounds in
humans. Studies have largely been limited to healthy volunteers
or animal models [6–9]. This may be because Mg is classed as a
nutritional supplement rather than medication [10] and also
perhaps because hypomagnesaemia, and its sequelae, are
under-recognized in clinical practice [11, 12].
Of a number of reports of Mg use in heart disease, asthma or
pre-eclampsia [13–15], none addressed either side effects orMg
formulation. Only one compound comparison study has been
published in patients with chronic gastrointestinal (GI) disor-
ders [16]; there are no studies of those with renal electrolyte
loss. The choice of Mg supplementation in clinical practice is
therefore usually decided on factors such as cost, compound
availability, and physician and/or patient preference.
High doses of Mg are often required to combat the excessive
urinary losses found in GS. However, oral Mg preparations are
frequently poorly tolerated due to their laxative and other GI
effects. A careful balance is required in order adequately to re-
place renal Mg loss without inducing counter-productive GI
Mg loss and this can present a therapeutic challenge. In an ef-
fort to improve efﬁcacy and quality of life in these patients, we
trialled the use of slow-release Mg lactate (SRMgL) in a cohort
with genetically proven GS and evaluated their experiences.
SRMgL is designed for twice-daily administration rather than
the thrice-(or more) daily requirement of other preparations.
MATERIALS AND METHODS
We approached patients with genetically proven GS currently
under care in our specialist nephrology clinic. All had previous-
ly provided ethically approved written consent for research
(NRES 08/H0306/62) and a purpose-designed questionnaire
was sent to them after a period of not <4 months since com-
mencing SRMgL. As well as collecting demographic, dose/
length of treatment and previous Mg treatment data, patients
were asked to report side effects, impact on GS symptoms,
residual GS symptoms and subjective opinion of impact on
their biochemical results. In addition, where Mg supplements
had previously been used, patients were invited to compare
their prior regimen with SRMgL in respect of side effects, num-
ber of tablets taken per day and ease of swallowing.
Based on the manufacturer’s claims for bioavailability, each
subject’s initial dose of SRMgL was calculated at two-thirds the
tablet number of their previous Mg formula, or in treatment-
naïve individuals, one tablet bd. Doses were titrated upward
to maximum tolerability and/or serum Mg >0.6 mmol/L (1.2
mEq) where possible; changing preparations tomaximize toler-
ability is a routine part of our clinical regimen. Questionnaire
responses were evaluated by quantitative and qualitative data
analysis.
We also retrospectively analysed serial biochemical data for
those patients for whom at least two pre- and four post-
commencement SRMgL values were available. The Mann–
Whitney U-test was used to compare mean pre-treatment and
post-treatment values, with statistical signiﬁcance determined
by P≤ 0.05, and Fisher’s exact test to compare proportions of
patients reaching target treatment values pre- and post-SRMgL.
RESULTS
From 37 invitations to participate, 28 questionnaires were re-
turned (76%) by 21 female and 7 male patients (3:1), with me-
dian age 39 years (range 20–74 years). Twenty patients (71%)
had formerly received treatment with maximally tolerable
doses of Mg glycerophosphate prior to switching to SRMgL.
An additional ﬁve patients had variously been prescribed Mg
oxide, Mg chloride, Mg aspartate or Mg glycinate prior to at-
tendance at our clinic, and three had not previously been treated
withMg supplements. Prior to switching, themedian daily dose
of Mg supplement in the 22 out of 25 for whom data were avail-
able was 7 tablets (range 4–32; 32–256 mEq Mg).
Given the difﬁculties of treating patients with high-dose Mg
compounds, patient responses were very positive regarding
SRMgL, with almost 90% (n = 25) choosing to continue long
term, and only 3 out of 28 discontinuing this medication in
favour of their previous preparation. Two of these three discon-
tinued SRMgL within 48 h due to difﬁculty swallowing the ta-
blets, which are caplets 2 cm in length. The third patient,
experiencing the same difﬁculty, broke the tablets in half (the
manufacturer’s information suggests this is acceptable; conse-
quently, the tablets are scored). However, this individual experi-
enced increasing stomach pain and had to discontinue
treatment after 3 weeks. Her gastric symptoms then resolved
spontaneously, although it is worth noting she had a prior his-
tory of gastro-oesophageal reﬂux disease requiring gastric fun-
doplication. A further three patients disliked the size of the
tablets but were able to continue. All six of these subjects had
previously received Mg therapy with a different preparation.
SRMgL doses in those continuing ranged from 2 to 18 tablets
daily (range 14–126 mEq Mg)/day with a median of 6 tablets
(42 mEq/day).
The overall rating of side effects in comparison with previous
Mg was favourable, with 13 (59%) patients reporting fewer side
effects, 7 (32%) describing them as the same and only 2 (9%)
considering side effects to be worse (one tolerated a minor in-
crease in laxative effect as they were able to reduce their total
number of tablets, one required extra Mg supplementation
when she became pregnant but was unable to tolerate more
than 10 tablets/day—shewas able to successfully take a combin-
ation of SRMgL and Mg glycerophosphate).
In common with all other Mg preparations, the laxative ef-
fect of SRMgL was the most frequently described side effect
among the cohort (Table 1). Unexpectedly, however, eight pa-
tients (32%) experienced no GI effects at all, with an additional
four (16%) commenting on only very mild loosening of stool.
Six subjects (25%) reported a moderate laxative effect (accom-
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patients (12.5%) suffering more severe GI upset, dose reduction
was sufﬁcient to improve tolerability in all, with all participants
eventually tolerating 2–12 tablets/day. The median dosage time
was 19 months (range 4–40). In the treatment-naïve subgroup,
one subject reported no GI side effects, one experienced mod-
erate laxative effect with stomach cramps and one commented
on increased thirst only.
Three patients were able to increase their SRMgL dose when
they experienced fewer side effects than with their previous
preparation, while twowere able to increase SRMgLwith a simi-
lar side-effect proﬁle. Two patients decided to take SRMgL in
combination with glycerophosphate as they said it beneﬁted
them best.
Patients were asked to evaluate the severity of their GS symp-
toms on SRMgL. In 17 cases (68%), they reported that symp-
toms had improved ‘a lot’ (n = 8) or ‘a little’ (n = 9). Seven
(28%) experienced no change and only one (4%) felt that his
symptoms were a little worse. None of the cohort described sig-
niﬁcant worsening of their overall clinical condition. In the
treatment-naïve subgroup, one subject described a good im-
provement in symptoms, one reported a small improvement
and one felt that symptoms were unchanged.
Notably, and contrary to the early GS literaturewhere the con-
dition was described as largely asymptomatic [17, 18], only six
(24%) subjects rated themselves as symptom free, while a further
three (12%) described GS symptoms as minor. Thus, 16 (64%)
patients continued to have residual GS symptoms.
Nineteen patients (76%), including two who were Mg naïve,
subjectively reported improvements in their serum electrolyte
levels, 6 (24%) reporting a good improvement and 13 (52%) a
modest improvement. In ﬁve cases (20%), electrolyte results
were thought by patients to be unchanged and one patient
(4%) thought blood results were a little worse since commen-
cing SRMgL. None of the group felt that their electrolyte levels
had signiﬁcantly deteriorated.
To evaluate these reports more objectively, we examined
serumMg and K values for the 23 patients with sufﬁcient avail-
able results; the number of measurements ranged from 2 to 124
(over up to 10 years pre-SRMgL) and 4–34 (over up to 5 years
post-SRMgL). Because blood results can be quite variable in GS,
we chose to compare the mean pre- and post-treatment values.
Overall, this analysis revealed that improvements were in fact
evident in 91% of this group (Figure 1). Eleven patients (48%)
improved both their Mg and K mean levels, three (13%) im-
proved Mg levels only and in seven cases (30%), only K levels
rose (Figure 2). Two (9%) made no gains in either Mg or K
mean levels; however, in both cases, levels were well above
our minimum target, and one of these (Figures 1 and 2, Patient
14) had been able to discontinue amiloride. The recorded gains
were variable and in some cases, gains in one value were offset
by modest falls in the other. We found that the post-treatment
improvements in K for the cohort reached statistical signiﬁ-
cance (P = 0.029), but those for Mg did not (P = 0.238). In 14
of the 23 cases, Mg and K moved in parallel (Figure 2).
We looked at how many of the 23 reached mean minimum
treatment target levels of serumMg≥0.60 mmol/L (≥1.2 mEq)
and serum K ≥3.2 mmol/L before and after treatment with
SRMgL. In respect of Mg values, 13 (57%) reached the mean
F IGURE 1 : Mean pre-SRMgL (white bars) and post-SRMgL (black
bars) potassium and magnesium values for the 23 patients who con-
tinued SRMgL.
Table 1. Reported side effects in 25 patients continuing SRMgL
Reported side effects No. of pts %
Difﬁculty swallowing tablets 3 12
None 8 32
Laxative effect: mild 4 16
Laxative effect: moderate 6 24
Laxative effect: severe/dose limiting 3 12
Abdominal cramps associated with laxative effect 2 8
Increased thirst 1 4
Insomnia 1 4
F IGURE 2 : Changes in pre-to-post mean potassium andmagnesium
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target pre- and 16 (69%) post-treatment (not different). For K
values, therewas a signiﬁcant difference (P = 0.024), with 20 pa-
tients (87%) reaching target levels post-treatment compared
with 13 (57%) prior.
Finally, patients who were not previously Mg naïve (22/25)
were asked to compare SRMgL with their prior Mg preparation.
Eleven of these (50%) reported being able to reduce the number
of Mg tablets consumed per day, and in all of these, Mg attained
or remained above our minimum target level. For example, Pa-
tient 8 (Supplementary data, Table S1) was able to reduce Mg
dosing by one-third, but both K and Mg levels rose. For a fur-
ther six (27%), the number of tablets taken daily was reported as
the same and ﬁve (23%) tolerated an increase to support their
Mg levels. A few individuals noted that the cost of their medica-
tions and the large number of pills they had to take contributed
in part to low perception of wellbeing.
DISCUSSION
We report here the subjective and biochemical effects of switch-
ingMg preparations in the context of the rare renal tubulopathy
GS. In the absence of clinical guidelines or other data concern-
ingMg preparations, we had taken a clinical decision to trial the
use of SRMgL after one of our patients reported a beneﬁcial
side-effect proﬁle, having purchased the tablets while in the
USA. Our early impressions of signiﬁcant improvement from
the patient’s perspective are supported by the results of this
audit.
Slow-release electrolyte preparations are more likely to pro-
vide stable therapeutic serum levels in patients with continuous
urinary electrolyte loss. This is borne out by the reported im-
provement in symptoms. However, symptom burden in GS
does not always correlate well with serum Mg values [5];
hence, blood results should be assessed in conjunction with
patient-reported outcomes. Our positive results are likely to re-
ﬂect the beneﬁts of the slow-release preparation rather than of
the lactate in the compound, for which there is no evidence of
speciﬁc beneﬁt, but we cannot state this deﬁnitively.
Clinical evaluation both of the degree of hypomagnesaemia
and the effectiveness of treatment are usually based on mea-
sured serum Mg values, yet there are a number of variables to
be taken into consideration in GS. There is poorly understood
day-to-day variability of both symptoms and electrolyte levels
[19]; individual variation in genotype, absorption of Mg,
exercise, ﬂuid intake/output, stress, gender, menstrual cycle
and concomitant illness may all inﬂuence the blood result
[5, 20–23]. Time of day of blood drawing is also of relevance,
particularly with the short-acting preparations, with values like-
ly to be lowest before breakfast and highest an hour or two after
a dose. Using the mean pre- and post-treatment values in our
biochemical analysis was therefore a strategic means of minim-
izing these potential confounders in a real-world clinical
setting.
The importance of achieving adequate Mg levels in main-
taining serum K is well recognized [24, 25]. Interestingly, the
mean serum K levels post-SRMgL in our patients improved
more readily than Mg levels themselves. This may be explained
by serum Mg not necessarily reﬂecting Mg storage, since <1%
of total body Mg is present in the serum [26]. Patients who
are chronically losingMg are likely to be total-bodyMg-deplete,
and replenishment will be accompanied by some redistribution
into exchangeable stores [27]. In addition, it is possible that
a smoothing of overall Mg levels by using a slow-release
compound supports stabilization of, or improvement in, K
levels.
A wide variety of Mg preparations is available in different
countries, most of which are classed as food supplements. For
these, there is no requirement to provide the same scientiﬁc evi-
dence to support bioavailability, efﬁcacy and tolerability as ap-
plies to medicines, and many health-food store-stocked Mg
compounds contain doses too low to be useful in GS. Labelling
of these ‘over the counter’ preparations is often not very inform-
ative and conforms to limited standards, although more strin-
gent labelling regulations were introduced in the USA in 2014
(www.crnusa.org/pdfs/DS-RegsLabel-0613.pdf ). In addition,
few Mg supplements are licensed; in the UK, this is limited to
Mg aspartate (www.medicinesresources.nhs.uk/GetDocument.
aspx?pageId=779639). In UK clinical practice outside nephrol-
ogy, Mg oxide has been the compound most frequently pre-
scribed, but it has much lower bioavailability than organic
formulae [9], and in ours and others’ experience, poor tolerabil-
ity when used in larger doses. Consequently, the choice of Mg
supplementation is often decided on physician preference
based on clinical experience and factors such as cost and com-
pound availability, rather than scientiﬁc evidence.
The management of GS has not changed signiﬁcantly over the
past four decades and there is an ongoing need for better treatment
options for this and other renal tubulopathies, and for formal re-
search into the pharmacodynamics of such treatments. Because of
the rarity of these conditions, adequately powered controlled trials
would be very difﬁcult to achieve, and the market for novel ther-
apieswould be small. Re-purposing knowndrugswould potential-
ly be possible, as demonstrated by Blanchard et al. [28], who
trialled the use of indomethacin in a cohort of GS patients. How-
ever, safety issues including adverse impacts on glomerular ﬁltra-
tion rate andGI epithelial integrity are likely to limit its adoption in
this particular scenario.
In our cohort, half of our patients have been able to reduce the
number of tablets taken daily, resulting in likely cost saving. In
addition, when treating a lifelong disorder such as GS, real sav-
ings can bemade by prescribing and orderingMgpreparations in
bulk [3]. However, in the setting of high, long-term requirement
for an unpalatable therapy such as Mg supplementation in a
small group of individuals, there is an argument for efﬁcacy, tol-
erability and/or patient preference outweighing cost considera-
tions. Positive patient-reported outcomes in this study suggest
that SRMgL is useful in the treatment of chronic hypomagnes-
aemia and a worthwhile addition to the prescriber’s formulary.
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